Dauricine

Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer^[1]. In Vitro:Dauricine (0-20 μM, 8 days) inhibits cell growth of HCT116, HCT8, SW620, and SW480 cells^[1].
Dauricine (0-20 μM, 12 and 24 h) causes G1 phase cell-cycle arrest in HCT116 cells^[1].
Dauricine (0-20 μM, 36 h) induces cell apoptosis and inhibits cell invasion in HCT116 cells^[1].
Dauricine (0-20 μM, 6 h) inhibits the activation of NF-κB signaling pathway in HCT116 cells^[1].
Dauricine (1 and 2 μg/mL, 24 h) inhibits glucose glycolysis and increased oxidative phosphorylation in HepG2 and Huh-7 cells^[3].
Dauricine (2 μg/mL, 48 h) increases the sensitivities of HCC cell lines to both Cisplatin (HY-17394) and Sorafenib (HY-10201)^[3].
In Vivo:Dauricine (s.c., 40 mg/kg, every 2-day. for 9 days) inhibits colonic tumor growth in a HCT116 xenograft mouse model^[1].
Dauricine (1 or 10 mg/kg, i.p.) ameliorates cognitive impairment, reduces Aβ Accumulation and Tau hyperphosphorylation in 3xTg-Alzheimer's Disease mice^[2].